Minimally Invasive Mitral Valve Repair at Medical City Dallas
The Dallas Valve Institute at Medical City Dallas Hospital now offers transcatheter mitral valve repair with MitraClip® therapy, providing a safe, minimally invasive option for symptomatic patients with significant degenerative mitral regurgitation who are at prohibitive risk for surgery.
A few of the clinical improvements include:
- Reduction in rate of hospitalization for heart failure
- Improvement in New York Heart Association (NYHA) Functional Class
- Reduction in mitral regurgitation severity
- Improvement in quality of life
- Reverse left ventricular (LV) remodeling
MitraClip® is the only FDA approved percutaneous therapy for degenerative mitral disease, and this technology is used for patients with prohibitive risk for open heart procedures.
To learn more about MitraClip® therapy, contact Dawn Palomares, or call (972) 566-5050.
Patient Success with MitraClip® Therapy
On Wednesday, August 26th, 2015, Dr. Bruce Bowers, HCA National Medical Director for Interventional Cardiology, and Dr. Todd Dewey, HCA National Medical Director for Cardiovascular Surgery implanted the first MitraClip® with great success.
Effectiveness of MitraClip® therapy for severe degenerative mitral regurgitation (DMR)
Certain high-surgical-risk patients with severe degenerative mitral regurgitation (DMR) now have a minimally invasive treatment option. MitraClip® therapy is a minimally-invasive transcatheter mitral valve repair (TMVr) procedure that has been established as a proven option with demonstrated safety and clinically important improvements.
Used in more than 25,000 patients worldwide, MitraClip® is a well-established therapy. The MitraClip® device received CE Mark approval in Europe in 2008 and U.S. FDA approval in 2013, and has been approved for commercial use in 50 countries throughout the world.